[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-prevention\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-prevention":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,52,95,122,149,176,204,228,260,273,299,325],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100053765","phase-4-ldl-c-optimization-using-inclisiran-in-patients-in-which-drug-drug-interactions-limit-ldl-lowering-100053765",false,"NCT06865885","LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering","Study of Optimal LDL-C Value Enhancement With Inclisiran in Patients With Multiple Comorbidities in Which There Are Drug-Drug Interactions Limiting LDL-C Lowering","SOLVE-LDL-C","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form.\n* Stated willingness to comply with all study procedures and availability for the duration of the study, including potential randomization to injections.\n* Age \\>18 and \\\u003C85 years and able to provide self-consent.\n* Taking five or more prescription drugs at the time of enrollment, of any type.\n* Meets at least one of the following criteria:\n\n  * Elevated 10-year ASCVD risk score ≥7.5% (based on the ACC\u002FAHA ASCVD Risk Estimator Plus tool).\n  * Evidence of subclinical atherosclerosis including:\n\nCalcification in any vascular bed, including coronary arteries and aorta. Calcification of cardiac valves. Breast calcification. Carotid plaque that is not hemodynamically significant.\n\no Type II diabetes on a stable medical regimen with HbA1c \\\u003C8.5%. Per American Diabetes Association guidelines, patients with Type II diabetes aged 40-75 years should be on a moderate-intensity statin.\n\nPatients with documented partial or complete statin intolerance are eligible for enrollment.\n\n* On maximally tolerated statin therapy (which can be no statin for patients with documented intolerance) and have suboptimal LDL levels:\n\n  * For patients with Type II diabetes: LDL \\>70 mg\u002FdL or non-HDL \\>120 mg\u002FdL.\n  * For other patients: LDL \\>90 mg\u002FdL or non-HDL \\>120 mg\u002FdL.\n* Willing to adhere to the randomized study regimen, including subcutaneous injection of inclisiran.\n* Agreement to adhere to lifestyle considerations (see Section 5.3) throughout the study duration.\n\nExclusion Criteria:\n\n* Prior or current use of inclisiran.\n* Known hypersensitivity or allergy to inclisiran or its components.\n* Active liver disease or unexplained persistent elevations in liver enzymes (ALT or AST \\>3x upper limit of normal).\n* History of rhabdomyolysis or severe muscle-related statin intolerance.\n* Uncontrolled diabetes (HbA1c \\>8.5%).\n* Active malignancy requiring systemic therapy.\n* Recent major cardiovascular event (myocardial infarction, stroke, or hospitalization for unstable angina) within the past 3 months.\n* History of organ transplant other than solid-organ transplant.\n* Pregnancy or breastfeeding.\n* Any condition that, in the opinion of the investigator, would make participation unsafe or interfere with study procedures.","ALL","18 Years","85 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","Drug-drug interactions often limit statin optimization in a population of patients prescribed cytochrome P3A4 inhibitors, which include immunosuppressive agents, protease inhibitors, and antifungals. These patients frequently have autoimmune conditions or rheumatologic disorders that require complex drug regimens and are often on low-dose statin therapy or no statin at all, resulting in suboptimal LDL levels despite increased cardiovascular (CV) risk.\n\nThere is an unmet clinical need to improve LDL levels in this vulnerable patient population, which faces increased CV risk due to underlying conditions that also contribute to polypharmacy and multiple drug-drug interactions. This study is a randomized, open-label trial evaluating subcutaneous inclisiran plus standard of care for LDL-C lowering in high-risk primary prevention patients with multiple comorbidities (e.g., Type II diabetes, liver disease, chronic kidney disease, autoimmune disease, solid-organ transplant) who are taking five or more medications in which drug-drug interactions prevent optimization of statin therapy.",[28,29,30,31],"Drug Interactions","Primary Prevention","Cardiometabolic Syndrome","LDL-Cholersterol Lowering",[33,34,35,36,37,38],"Statin intolerance","drug drug interaction","inclisiran","LDL-Cholesterol","polypharmacy","multiple comorbidities","RECRUITING","2026-07-10",{"date":42,"type":43},"2026-07-13","ACTUAL",{"date":45,"type":43},"2025-04-02",{"date":47,"type":22},"2027-03-31",{"name":49,"class":50},"University of California, San Diego","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":61,"minAge":18,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":23,"phases":65,"briefSummary":67,"conditions":68,"keywords":75,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":4},"100638958","immune-mitochondrial-correction-in-military-recruits-100638958","NCT07622147","Immune-Mitochondrial Correction in Military Recruits","A Parallel-Group, Participant-Blinded Comparative Trial of an Immuno-Mitochondrial Correction Strategy (Sodium Nucleinate + Magnesium\u002FPyridoxine + Vitamin D3 5000 IU) Versus Standard Multivitamin Prophylaxis to Reduce Respiratory Infection Incidence in Male Military Recruits During the 6-Month Adaptation Period","IMMU-MITO","Inclusion Criteria:\n\n* Male military recruits aged 18-27 years\n* Starting initial military training at the Military Clinical Hospital of the Ministry of Defense of the Republic of Kazakhstan (Almaty)\n* Signed informed consent\n* No acute infectious diseases at enrollment\n* Willingness to comply with the study protocol for 6 months\n* Absence of any exclusion criteria\n\nExclusion Criteria:\n\n* Chronic immunodeficiency states (HIV infection, congenital immunodeficiencies, current immunosuppressive therapy)\n* Severe chronic diseases in decompensation stage (diabetes mellitus, renal failure, hepatic failure, heart failure)\n* Allergy or hypersensitivity to any components of the study interventions (multivitamin, sodium nucleinate, magnesium, vitamin B6, vitamin D)\n* Use of vitamin-mineral complexes or immunomodulators within the last 3 months prior to enrollment\n* Hypercalcemia (serum calcium \\>2.6 mmol\u002FL) or history of urolithiasis\n* Hypermagnesemia (serum magnesium \\>1.1 mmol\u002FL)\n* Sarcoidosis or other granulomatous diseases\n* Refusal or inability to provide informed consent",true,"MALE","27 Years",{"count":64,"type":22},200,[66],"NA","The goal of this clinical trial is to learn if a new immune-mitochondrial correction strategy works better than standard vitamins to prevent infections in young male military recruits during their first 6 months of service.\n\nThe main questions it aims to answer are:\n\n1. Does the new strategy lower the number of recruits who get infections (like colds, flu, or pneumonia) over 6 months?\n2. Does the new strategy improve how well the immune cells work, specifically their mitochondria (the power source inside cells)?\n\nResearchers will compare:\n\n* Control group (100 participants): Standard multivitamin taken once a day for 30 days\n* Experimental group (100 participants): New strategy (sodium nucleinate, magnesium, vitamin B6, and vitamin D 5000 IU) taken as 3 tablets once a day for 30 days to see if the new strategy lowers infection rates more than standard vitamins.\n\nWho can take part:\n\nHealthy male military recruits aged 18-27 years who are starting their initial training at the Military Clinical Hospital in Almaty, Kazakhstan.\n\nWhat participants will do:\n\nParticipants will be placed into one of the two groups by chance (like flipping a coin). They will:\n\n* Take study pills once a day for 30 days\n* Have blood draws 3 times over 6 months (baseline, 1 month, and 6 months)\n* Have daily health checks by medical staff\n* Complete quality of life questionnaires\n\nWhat we will measure:\n\n* Number of participants who get infections during 6 months\n* How well the mitochondria in immune cells work (from blood samples)\n* Immune system status\n* Stress and adaptation levels\n* Vitamin D and other blood markers\n\nRisks and benefits:\n\nThe risks are very low. Participants may have mild discomfort or a small bruise from blood draws. All study pills are approved and registered in Kazakhstan.\n\nThere is no direct benefit to participants, but they will receive extra medical monitoring. The indirect benefit is helping develop a better prevention program to protect future recruits.\n\nWhere the study is taking place:\n\nMilitary Clinical Hospital of the Ministry of Defense of the Republic of Kazakhstan, Almaty, Kazakhstan.\n\nStudy duration:\n\nJanuary 2027 to December 2028.",[69,70,71,29,72,73,74],"Respiratory Tract Infections (RTI)","Meningitis","Primary Prevention\u002FMethods","Mitochondrial Biomarkers","Immuno-monitoring","Immuno-modulation",[76,77,78,79,80,81,82,83,84],"Military recruits","Infection prevention","Immunocorrection","Mitochondrial function","Sodium nucleinate","Vitamin D","Respiratory infections","Stress adaptation","Randomized controlled trial","NOT_YET_RECRUITING","2026-06-24",{"date":88,"type":43},"2026-06-29",{"date":90,"type":22},"2027-01-01",{"date":92,"type":22},"2028-12",{"name":94,"class":50},"MIPO Clinic",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":121},"100499287","multicentre-randomised-study-comparing-a-taurolidine-lock-and-a-standard-saline-lock-in-paediatric-oncology-100499287","NCT05781295","Multicentre Randomised Study Comparing a Taurolidine Lock and a Standard Saline Lock in Paediatric Oncology","Multicentre Randomised Study Comparing a Taurolidine Lock and a Standard Saline Lock in the Primary Prevention of Catheter-related Endoluminal Infection in Paediatric Oncology.","PEDIALOCK","Inclusion Criteria:\n\n1. Patient less than or equal to 21 years of age at inclusion.\n2. Patient for whom a central catheter is planned to be inserted\\*, excluding a non-tunneled femoral or cervical external catheter or a peripherally inserted central catheter (as PICC line). \\*1st catheter placement or placement following a relapse (this placement must take place at least one month after previous catheter removal).\n3. Patient treated for a cancer.\n4. Patient with regular follow-up in the inclusion center.\n5. Informed consent signed by the patient if adult or by legal representatives if minor.\n6. Patient benefiting from a social security coverage.\n7. Time between the date of catheter placement and the planned date for the first solution lock injection less than 6 weeks.\n\nExclusion Criteria:\n\n1. Patient with retinoblastoma.\n2. Allografted patient.\n3. Patient with a life expectancy of less than 6 months.\n4. Patient refusing to participate in the protocol.\n5. Patient already receiving a central venous catheter-related infection prevention lock (ILCVC).\n6. Patient with known allergy to citrate or (cyclo)-Taurolidine.\n7. Patient taking other drugs with a known contraindication with citrate or (cyclo)-Taurolidine.\n8. Patient with an external femoral catheter.\n9. Patient with a PICCLINE-type peripheral venous inserted central catheter.\n10. Patient unable to submit to the medical follow-up of the trial for geographical, social or psychological reasons.\n11. Patient under guardianship and curatorship.","21 Years",{"count":105,"type":22},148,[66],"Interest of a Taurolidine lock at each catheter closure in the primary prevention of catheter-related endoluminal infection in paediatric oncology.\n\nMulticentric, controlled, randomized and double-blind label study.",[109,110,29,111],"Children","Medical Device","Oncology","2026-02-18",{"date":114,"type":43},"2026-02-20",{"date":116,"type":43},"2024-01-19",{"date":118,"type":22},"2028-07-23",{"name":120,"class":50},"Institut Curie",5,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":60,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":132,"phases":4,"briefSummary":133,"conditions":134,"keywords":138,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":51},"100620504","delphi-procedure-for-developing-recommendations-for-the-implementation-of-wearable-devices-and-polygenic-risk-scores-100620504","NCT07358481","DELphi Procedure for Developing Recommendations for the Implementation of Wearable Devices and Polygenic Risk Scores","DEL-DIP: DELphi Procedure for Developing Recommendations for the Implementation of Wearable Devices and Polygenic Risk Scores","DEL-DIP","Inclusion criteria\n\n* Experts in cardiology\n* Experts in personalized medicine\n* Experts in digital health.\n\nExclusion criteria\n\n\\- Failure to provide informed consent (i.e., non-acceptance of the informed consent form)",{"count":131,"type":22},10,"OBSERVATIONAL","DEL-DIP is a prospective observational study employing a Delphi methodology (at least two online rounds) to elicit and consolidate the views of an expert panel within the INNOPREV project. The study aims to develop operational recommendations to support the coordinated implementation of Polygenic Risk Scores (PRS) and wearable devices in cardiovascular prevention. Specifically, it addresses the following research question: which recommendations and requirements-genomic, digital, and clinical\u002Forganizational-are necessary to integrate PRS and wearable technologies into routine practice and healthcare services, and for which of these elements do experts achieve consensus (defined as a Content Validity Index, CVI, \\> 79%)",[135,136,137,29],"Wearable Electronic Devices","Polygenic Risk Score","CVD - Cardiovascular Disease",[139],"cardiovascular prevention","2026-01-22",{"date":142,"type":43},"2026-01-23",{"date":144,"type":22},"2026-02",{"date":146,"type":22},"2026-04",{"name":148,"class":50},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":17,"minAge":156,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":23,"phases":159,"briefSummary":160,"conditions":161,"keywords":163,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":51},"100571612","phase-4-guide-cac-statin-ezetimibe-without-aspirin-vs-statin-monotherapy-with-aspirin-in-high-coronary-calcification-100571612","NCT06722521","GUIDE-CAC: Statin-Ezetimibe Without Aspirin vs. Statin Monotherapy With Aspirin in High Coronary Calcification","Comparison of Intensive Lipid-Lowering Therapy With a Statin-Ezetimibe Combination (Without Aspirin) vs. Statin Monotherapy (With Aspirin) In Asymptomatic Patient With Coronary Artery Calcification","Inclusion Criteria\n\n1. Adults aged 19 years and older\n2. Asymptomatic patients with significant coronary calcification (Agatston score ≥ 100) and no physiologically significant coronary artery disease (CAD)\n\n   * The coronary CT scan used to establish the CAC score must be performed within 3 years prior to randomization.\n   * The assessment of physiological significance must be performed within 6 months prior to randomization\n3. Participants will be eligible for inclusion regardless of prior statin or anti-platelet agents use.\n\nExclusion Criteria\n\n1. Major ASCVD events (clinically documented ASCVD)\n\n   If at least one of the following criteria is present via patient history, physical examination, or medical records at the time of screening, the patient is not eligible:\n   * Acute coronary syndrome (MI or unstable angina)\n   * Coronary revascularization (PCI, CABG) or other arterial revascularization\n   * Ischemic stroke (Not TIA)\n   * Symptomatic peripheral arterial disease (history of claudication with ABI \\\u003C0.90, or previous revascularization or amputation\n2. Patients with physiologically significant CAD\n\n   * Moderate to severe CAD (diameter stenosis \\>50%) on CCTA with positive strest test (thallium, treadmil, stress echocardiography)\n   * Moderate to severe CAD (diameter stenosis \\>50%) on CAG with positive fractional flow reserve (FFR) \\\u003C 0.8\n3. Patients with familial hypercholesterolemia.\n4. Patients with low-density lipoproteins cholesterol (LDL-C) ≥ 190 mg\u002FdL regardless taking a statin or not.\n5. Continuation of PCSK9 inhibitor is required during the clinical trial\n6. Patients with chronic kidney disease (\\\u003CeGFR 30mL\u002Fmin\u002F1.73m2)\n7. Advanced liver disease (Child-Pugh B or C)\n8. Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (ALT or AST \\> 5 times upper limit of normal).\n9. History of gastrointestinal bleeding, peptic ulcer, or intracranial hemorrhage within 6 months prior screening\n10. Patients with a history of organ transplantation who are on immunosuppressive therapy\n11. Concurrent use of other medications that may increase bleeding risk such NOAC and warfarin\n12. A history of significant allergic reaction to aspirin or statin\u002Fezetimibe\n13. A diagnosis of cancer (other than superficial squamous or basal cell skin cancer) in the past 3 years or current treatment for the active cancer.\n14. Life expectancy \\\u003C 1 years for any non-cardiac or cardiac causes.\n15. Patient's pregnant or breast-feeding or child-bearing potential.\n16. Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study.\n17. Unwillingness or inability to comply with the procedures described in this protocol","19 Years",{"count":158,"type":22},7435,[25],"A Multicenter, randomized trial comparing the efficacy and safety of intensive lipid-lowering therapy using a statin-ezetimibe combination without aspirin versus statin monotherapy with aspirin in asymptomatic patients with coronary artery calcification",[29,162],"Vascular Calcification",[164,165,166],"Cardiovascular Diseases","Aspirin","Statin","2025-08-04",{"date":169,"type":43},"2025-08-07",{"date":171,"type":43},"2025-07-09",{"date":173,"type":22},"2032-10-31",{"name":175,"class":50},"Asan Medical Center",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":17,"minAge":182,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":23,"phases":186,"briefSummary":187,"conditions":188,"keywords":192,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":51},"100596451","comparison-of-intensive-versus-standard-care--education-for-dyslipidemia-in-hypertension-and-diabetes-patients-100596451","NCT07045623","Comparison of Intensive Versus Standard Care & Education for Dyslipidemia in Hypertension and Diabetes Patients","Inclusion Criteria:\n\n* Patients registered in the Hanam City Hypertension and Diabetes Program\n* Adults aged 30 to 80 years\n* Individuals who have provided written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Chronic kidney disease stage 4 or higher (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²)\n* Patients with liver cirrhosis or severe liver disease\n* Patients with a history of acute coronary syndrome within the past 6 months\n* Pregnant or breastfeeding women • Individuals with psychiatric disorders that may affect study participation","30 Years","80 Years",{"count":185,"type":22},348,[66],"The prevalence of dyslipidemia is high among patients with hypertension and diabetes mellitus, which increases the risk of cardiovascular disease. However, many patients lack awareness and adherence to treatment and lifestyle modifications. Therefore, a more structured and intensive approach to management and education is required.\n\nThis study aims to implement intensive dyslipidemia management and education for patients registered at the Hanam City Hypertension and Diabetes Education Center and evaluate changes in blood lipid levels accordingly. Additionally, the study will analyze the impact of intensive education on patients' quality of life, health behaviors, and treatment adherence, ultimately contributing to the development of effective management strategies.",[189,190,191,29],"Hypertension","Diabetes Mellitus","Dyslipidemia",[193,194,191],"Primary prevention","Chronic disease","2025-06-22",{"date":197,"type":43},"2025-07-01",{"date":199,"type":43},"2025-04-01",{"date":201,"type":22},"2026-06-30",{"name":203,"class":50},"Saint Vincent's Hospital, Korea",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":17,"minAge":156,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":23,"phases":214,"briefSummary":215,"conditions":216,"keywords":219,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":51},"100530381","phase-4-clinical-comparison-of-low-dose-rosuvastatin-plus-ezetimibe-combination-therapy-and-high-dose-rosuvastatin-monotherapy-in-patients-with-minimal-to-intermediate-coronary-artery-disease-without-percutaneous-coronary-intervention-100530381","NCT06186037","Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention","Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention : A Prospective, Multicenter, Randomized, Open-label Trial","ALMIGHTY","Inclusion Criteria:\n\n1. Male and female adjusts (19 or older)\n2. Patients with suspected stable angina pectoris without coronary artery interventions, who showed a minimal to intermediate coronary artery diseases (a stenosis of 10 to 70% diameter as per QCA) in at least one natural coronary artery in coronary artery angiography or coronary artery CT.\n3. Patients who gave their informed consent themselves in writing.\n4. Patients who were treated with statin or lipid-lowering agents may participate in the study by changing the existing medicines.\n\nExclusion Criteria:\n\n1. Patients with an intermediate (\\>30%) lesion on the left main coronary artery.\n2. Patients diagnosed with acute coronary artery diseases (STEMI, NSTEMI, Unstable angina)\n3. Patients who received percutaneous coronary intervention\n4. Patients who have been diagnosed with stroke, transitory ischemic attack, and peripheral artery diseases.\n5. Patients diagnosed with variant myocardial infarction\n6. Patients with severe liver diseases or lung diseases and\u002For malignant tumor with life expectancy of less than 3 years\n7. Patients with severe valvular heart disease\n8. Patients who are hypersensitive or prohibited from using the active substance (Ezetimibe or Rosuvastatin) of the study medicines\n9. Patients with cardiogenic shock\n10. Pregnant women or women who are planning to get pregnant\n11. Patients who are receiving hemodialysis or peritoneal dialysis or received renal transplantation due to end-stage renal failure\n12. Patients who participated in other clinical studies within the past three months (except for non-interventional observation studies)",{"count":213,"type":22},6356,[25],"\\[Purpose of the Clinical Study\\]:The purpose of this study is to conduct a clinical comparison of low-dose rosuvastatin plus ezetimibe combination therapy and high-dose rosuvastatin monotherapy in patients with minimal to intermediate coronary artery disease without percutaneous coronary intervention to confirm non-inferiority in the reduction of key cardiovascular events.\n\n\\[Hypothesis\\]:In patients who have not undergone percutaneous coronary intervention for minimal to moderate coronary artery disease, low-dose rosuvastatin and ezetimibe combination therapy are non-inferior in terms of reducing major cardiovascular events compared to high-dose rosuvastatin monotherapy.",[217,218,29],"Coronary Artery Disease","Dyslipidemias",[217,218,29],"2025-06-19",{"date":222,"type":43},"2025-06-25",{"date":224,"type":43},"2024-02-01",{"date":226,"type":22},"2029-02-28",{"name":203,"class":50},{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":17,"minAge":236,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":23,"phases":239,"briefSummary":240,"conditions":241,"keywords":245,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":51},"100515611","non-pharmacological-prevention-of-pod-in-frailty-elderly-undergoing-elective-surgery-applied-by-nursing-teams-100515611","NCT05993754","Non-pharmacological Prevention of POD in Frailty Elderly Undergoing Elective Surgery Applied by Nursing Teams","Impact of Non-pharmacological Measures Applied by the Nursing Team in Reducing the Incidence of Postoperative Delirium During the Postoperative and 24hr After Surgery in Frail Elderly Undergoing Elective Non-cardiac Surgeries.","NPPOD","Inclusion Criteria:\n\n* Patients older than 65 years\n* Elective non-cardiac surgery\n* General anesthesia with Bilateral BIS electroencephalographic monitoring or SedLine\n* ASA I, II or III.\n\nExclusion Criteria:\n\n* Neurosurgical patients\n* History of alcohol and\u002For drug abuse\n* History of recreational psychoactive drug use\n* Allergy to anesthetic drugs.","65 Years",{"count":238,"type":22},400,[66],"The increase in the population over 60 years of age who could receive surgery due to changes in life expectancy and advances in surgical and anesthetic techniques.\n\nLikewise, elderly people (EP) may have a higher risk of postoperative morbidity and mortality compared to young people, with frailty being one of the risk factors that increases adverse outcomes in this period and increases the probability of developing syndromes such as postoperative delirium (POD).\n\nAssessment of frailty in EP prior to surgery is not routine, so it is unknown how many frail and\u002For pre-frail EP undergo surgery in health care systems. There is an association between being frail and developing greater delirium and\u002For postoperative cognitive deficit, which in summary translates into an increase in perioperative morbidity and mortality.\n\nFor the prevention of POD, there are pharmacological and non-pharmacological measures that seek to promote orientation with respect to their environment and make it as familiar as possible, stimulate early aspects of memory and thinking skills, as well as promote sleep using environmental hygiene measures.\n\nIn Chile, protocols of non-pharmacological measures have been proposed by occupational therapy teams, which have had positive results in reducing POD in frail elderly patients. These measures are temporal-spatial reorientation, physical mobilization, correction of sensory deficits, environmental management, sleep protocol, and reduction of anticholinergic drugs with statistically significant results in the reduction of POD.\n\nIn accordance with the above, the objective of this study is to evaluate the impact of non-pharmacological measures applied by the nursing team in reducing the incidence of POD during the post-surgical period in fragile and pre-fragile EP undergoing elective non-cardiac surgeries.\n\nIt is expected that in the end, frail and pre-frail EP who receive non-pharmacological interventions by the nursing team will present a lower incidence of POD at 24 hours compared to those who receive traditional care.",[242,29,243,244],"Frail Elderly Syndrome","Postoperative Delirium","Frailty",[246,247,248,244,249,250],"Delirium","Non-pharmacological","Elderly","Nursing","Postoperative","2025-06-05",{"date":253,"type":43},"2025-06-10",{"date":255,"type":43},"2024-04-01",{"date":257,"type":22},"2026-12-31",{"name":259,"class":50},"Pontificia Universidad Catolica de Chile",{"id":261,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":262,"targetDuration":4,"studyType":23,"phases":263,"briefSummary":26,"conditions":264,"keywords":265,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":272,"locationsCount":51},"100582636",{"count":21,"type":22},[25],[28,29,30,31],[33,34,35,36,37,38],"2025-04-08",{"date":268,"type":43},"2025-04-11",{"date":270,"type":43},"2025-04-03",{"date":257,"type":22},{"name":49,"class":50},{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":11,"sex":17,"minAge":281,"maxAge":282,"enrollmentInfo":283,"targetDuration":4,"studyType":23,"phases":285,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":51},"100494970","role-of-coronary-cta-on-lipid-management-and-risk-factors-control-in-an-asymptomatic-chinese-population-100494970","NCT05725096","Role of Coronary CTA on Lipid Management and Risk Factors Control in an Asymptomatic Chinese Population","Role of the Screening with Coronary Computed Tomography Angiography on Lipid Management and Risk Factors Control in an Asymptomatic Chinese Population: a Community-based, Prospective Randomised Trial","RESPECT2","Inclusion Criteria:\n\n1. Nanjing residents who have no plans to leave in the next 5 years\n2. Aged from 40 to 69 years\n3. Free of any known clinically cardiovascular disease Able to comprehend and sign an informed consent form\n\nExclusion Criteria:\n\n1. Serious liver dysfunction, defined as AST or ALT \\> 3 times the normal upper limit\n2. Chronic kidney disease (CKD) \\> stage 4, defined as eGFR \\\u003C 30 ml\u002Fmin\u002F1.73 m2\n3. Prior CCTA or invasive coronary angiography within the last 5 years\n4. Any contraindications for CCTA\n5. Previous use of statin or non-statin lipid-lowering medication (such as ezetimibe, PCSK9 inhibitor and XueZhiKang)\n6. Life expectancy \\\u003C 3 years\n7. Other reasons the researcher deems inappropriate to attend","40 Years","69 Years",{"count":284,"type":22},3400,[66],"The primary objective of this study is to determine whether coronary computed tomography angiography (CCTA) -based coronary heart disease(CHD) prevention strategy improves lipid-lowering treatment and cardiovascular risk factor control compared with traditional CHD prevention strategy, guided by a cardiovascular risk score.",[166,288,29,289],"Cardiovascular Risk Factors","Adherence, Medication","2024-11-25",{"date":292,"type":43},"2024-11-26",{"date":294,"type":43},"2023-06-28",{"date":296,"type":22},"2027-06",{"name":298,"class":50},"Zhang longjiang,MD",{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":60,"sex":17,"minAge":306,"maxAge":307,"enrollmentInfo":308,"targetDuration":4,"studyType":23,"phases":310,"briefSummary":311,"conditions":312,"keywords":313,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":51},"100563409","fit-first-teen---school-intervention-study-100563409","NCT06615791","FIT FIRST Teen - School Intervention Study","FIT FIRST Teen Effectiveness and School Implementation Study - a Cluster Randomised Mixed Methods Trial.","Inclusion Criteria:\n\n* part of the enrolled classes\n\nExclusion Criteria:\n\n* none","13 Years","16 Years",{"count":309,"type":22},912,[66],"The goal of this cluster randomised controlled trial is to investigate the effects of the FIT FIRST Teen program on adolescents' physical fitness, motivation, and well-being, as well as the implementation of such a program within schools. The main questions it aims to answer are:\n\nResearch Question 1: Does the FIT FIRST Teen program improve cardiorespiratory fitness, body composition, and muscle strength among adolescents?\n\nResearch Question 2: Does the FIT FIRST Teen program improve well-being, motivation towards physical activity, and body image among adolescents?\n\nResearch Question 3: What are the challenges that teachers and schools will face regarding the implementation of the FIT FIRST Teen program?\n\nThe research team will compare the FIT FIRST Teen program to a control (usual physical education curricula) to see if such a program improves adolescents' physical fitness, motivation, and well-being. Participating schools will:\n\n* Participate in a training course, where the core principles of the FIT FIRST Teen program will be delivered.\n* Implement the FIT FIRST Teen program for a full school year (three 45-minute lessons a week).\n* Keep a logbook where the weekly practised activities will be reported.",[29],[314,315],"physical activity","sports","2024-09-24",{"date":318,"type":43},"2024-09-27",{"date":320,"type":43},"2024-08-15",{"date":322,"type":22},"2025-06-30",{"name":324,"class":50},"University of Southern Denmark",{"id":326,"slug":327,"hasResults":11,"nctId":328,"briefTitle":329,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":23,"phases":333,"briefSummary":334,"conditions":335,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":4},"100562547","the-parental-journey-digital-tool-for-security-in-parenthood-a-way-to-promote-public-health-a-pilot-study-100562547","NCT06604585","The Parental Journey. Digital Tool for Security in Parenthood, a Way to Promote Public Health. A Pilot Study.","Inclusion Criteria:\n\n* Adult parents (or another adult who is a primary caregiver) to children within pediatric healthcare services with children aged 2-5 years old.\n* The parents are not participating in other parental support programs or interventions from Child Health Care psychologists, as this would complicate the evaluation of the effects of each intervention.\n* Parents who speak Swedish, due to the fact that \"Parenting - a journey together\" has not yet been translated into other languages.\n* Parents who respond affirmatively to the inclusion questions, indicating that they perceive a need for additional parental support and are motivated to participate in the program.\n\nInclusion questions for assessing a parent's needs and motivation to participate in the digital parenting support program:\n\n1. How important do you consider your ability\u002Fconfidence as a parent to be for you right now?\n2. What has motivated you to consider participating in this program?\n3. How motivated are you to make changes in your behavior to improve your parenting ability?\n4. Do you have previous experiences with similar digital programs or parental support interventions? If yes, what was your experience?\n5. What type of support do you think you need to successfully complete this program?\n\nExclusion Criteria:\n\n* Parents of children outside the 2-5 years age range. The program is specifically designed for parents within child health care with children in this age group. Once children reach the age of 6, they transition to school health care.\n* The parents who are already participating in other parental support programs or receiving interventions from Child Health Care psychologists are not eligible, as this would complicate the evaluation of the effects of each intervention.\n* Parents who do not speak Swedish, as the program 'Parenting - a Journey Together' has not yet been translated into other languages.\n* Parents who have indicated no perceived need for additional parental support.",{"count":332,"type":22},30,[66],"The goal of this randomized clinical pilot study is to evaluate the feasibility and experience of the internet-based parental support program \"Parenting - a journey together\". This program is intended to be delivered via the national Support and Treatment Platform and used within primary care to enhance traditional parental support within child health care when needed. The main questions it aims to answer are:\n\n1. Is the digital parental support intervention feasible and helpful within primary care?\n2. How do parents perceive the program \"Parenting - a journey together\"?\n3. Does the program increase the sense of parental ability and security in parenting by reflecting on attitudes and approaches in interaction with the child?\n\nParticipants in this study will be parents of children aged 2-5 years who have expressed interest in participating in the study and in the parental support program. Participants will be randomized into either the intervention group or the control group. Participants will be asked to complete validated questionnaires measuring the parent-child relationship, perceived parental ability, stress, and well-being before and after the parental support program, and again after 3 months. These results will then be compared with those of the control group.The knowledge gained from the pilot study can contribute to the development of digital parental support interventions within primary care. If the pilot study proves that the interactive digital parenting program is feasible for use in child health centers and is perceived as helpful by parents, a larger randomized controlled (RCT) study, (not included in this application) will be conducted to evaluate its effectiveness.",[29,336,337],"Parenting","Family Relations","2024-09-17",{"date":340,"type":43},"2024-09-19",{"date":342,"type":22},"2024-11",{"date":344,"type":22},"2026-11",{"name":346,"class":347},"Vastra Gotaland Region","OTHER_GOV"]